On November 18, Summit Therapeutics PLC fell 4.12% in Pre-Market Trading to $10.33 per share, with turnover of $706,300.
The move followed the company’s announcement that it has initiated a global phase 3 trial of ivonescimab in patients with locally advanced, inoperable non-small cell lung cancer, comparing the drug with durvalumab as maintenance treatment after chemoradiation, with progression-free survival as the primary endpoint and global site activation expected in the fourth quarter.
However, the new trial appears insufficient to fully reverse regulatory concerns after the FDA recently issued a complete response letter rejecting ivonescimab for previously treated advanced lung cancer. The agency said that, without demonstrated overall survival improvement, progression-free survival benefit alone was not enough to support a favorable benefit-risk balance, leaving the timing and path of any resubmission uncertain.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments